---
title: "Aimia To Sell Its Stake In Giovanni Bozzetto To One Equity Partners"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275327761.md"
description: "Aimia Inc. (AIM.TO) announced the sale of its stake in Giovanni Bozzetto S.p.A to One Equity Partners for C$265 to C$271 million. The transaction is expected to close within three months and is part of Aimia's strategy to enhance shareholder value. Proceeds will be used to strengthen the balance sheet and support acquisitions. Aimia's stock is currently trading at C$3.06, up 1.66% on the Toronto Exchange."
datetime: "2026-02-09T13:54:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275327761.md)
  - [en](https://longbridge.com/en/news/275327761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275327761.md)
generator: "portal-rs"
---

# Aimia To Sell Its Stake In Giovanni Bozzetto To One Equity Partners

Add  as your preferred news source on Google

 Add Now

Aimia Inc. (AIM.TO), Monday announced an agreement agreement to sell its interest in Giovanni Bozzetto S.p.A, a specialty chemicals business, to One Equity Partners for a purchase price in a range of C$265 to C$271 million.

The transaction, which is expected to close within the next three months, is a part of the company's three-step strategy to drive shareholder value creation.

Aimia intends to use the proceeds to strengthen its balance sheet and support its plans to acquire controlling interests in operating companies. 

Currently, Aimia's stock is trading at C$3.06, up 1.66 percent on the Toronto Exchange. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [Aim Immunotech’s Aggressive Equity Issuance Raises $10.4M but Poses Major Dilution Risk for Shareholders](https://longbridge.com/en/news/295371378.md)
- [AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million](https://longbridge.com/en/news/295152135.md)
- [AIM ImmunoTech completes last dosing in Phase 2 DURIPANC trial of Ampligen plus AstraZeneca Imfinzi in metastatic pancreatic cancer](https://longbridge.com/en/news/294694088.md)
- [Aimia Steps Up Share Buybacks to Narrow Discount to Intrinsic Value](https://longbridge.com/en/news/281412274.md)
- [AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program | AIM Stock News](https://longbridge.com/en/news/291938661.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**